Clinical trials: Higher Risk Myelodysplastic Syndrome
Acute Myeloid Leukemia, MDS
ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS
ClAraC (consisting of one dose of clofarabine and ara-C for five days) or FLAMSA (consisting of one dose of fudarabine, amsacrine and ara-C for four days) will be administered followed by reduced-intensity conditioning regimen…
- Trial name
- ClAraC-SCT (NCT01423175)
- Testing
- Clofarabine, ara-C, FLAMSA
- Where
- 3 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Hannover Medical School
Leukemia
Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure
The goal of this clinical research study is learn if omacetaxine can help to control myelodysplastic syndrome (MDS). The safety of this drug will also be studied. This is an investigational study.
- Trial name
- NCT02159872
- Testing
- Omacetaxine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia (AML)
A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)
There was no well accepted standard of care for participants who failed or were intolerant to any of the currently approved therapies for myelodysplastic syndromes (MDS).
- Trial name
- NCT00531232
- Testing
- Clofarabine
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Genzyme, a Sanofi Company
Myelodysplastic Syndromes
A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts
The objectives of this phase II trial are to test the efficacy and tolerance of Bevacizumab in MDS patients with excess of marrow blasts and to evaluate the impact of Bevacizumab on angiogenesis and erythropoiesis.
- Trial name
- NCT00565656
- Testing
- BEVACIZUMAB
- Where
- 10 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Effectiveness of Protected Environment Rooms for AML and MDS
The goal of this clinical research study is to learn if the "protected environment" (PE) can help to prevent infections in patients aged 60 and above who are receiving what is considered low-intensity treatment for…
- Trial name
- NCT00443300
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndrome, Acute Myeloid Leukemia
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
This multi center open label Phase 1b study is designed to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of glasdegib (PF-04449913) when combined with azacitidine in patients with previously…
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- BRIGHT 1012 (NCT02367456)
- Testing
- PF-04449913 (Glasdegib), Azacitidine
- Where
- 33 sites in United States, Belgium and 4 more
- Volunteers
- 73 people
- Sponsor
- Pfizer
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT00963872
- Testing
- cyclophosphamide, fludarabine phosphate, Total body irradiation
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myelodysplastic Syndrome
Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)
For MDS patients who have not responded to or have progressed after an initial response to DNA methyltransferase inhibitors (DNMTI) and are not stem cell transplant candidates, therapeutic options are limited.
- Trial name
- NCT00867061
- Testing
- ON 01910.Na Concentrate
- Where
- United States
- Sponsor
- Traws Pharma, Inc.
Leukemia
Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if omacetaxine given with cytarabine can help to control the disease in patients with AML or high-risk MDS. The safety of the study drugs will also be studied.
- Trial name
- NCT01272245
- Testing
- Omacetaxine, Cytarabine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
To learn if olutasidenib, when combined with a drug called a hypomethylating agent (HMA) can help to control MDS, CMML, and/or MPN. The safety of the drug combination will also be studied.
- Conditions
- Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms, IDH1-mutated Higher-Risk Myelodysplastic Syndromes
- Trial name
- NCT06597734
- Testing
- Olutasidenib
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
This study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).
- Trial name
- ImmBridge (NCT06918834)
- Testing
- Immediate HSCT Group, Bridging Therapy Group
- Where
- 5 sites in China
- Volunteers
- 236 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
This phase II MyeloMATCH treatment substudy tests the addition of olutasidenib to usual treatment in patients with higher-risk myelodysplastic syndrome (MDS) or patients with acute myeloid leukemia (AML) with a mutation in the…
- Trial name
- NCT07153497
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
This research study is studying a targeted therapy combined with chemotherapy as a possible treatment for acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
- Trial name
- NCT03735446
- Testing
- Prexasertib, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Dana-Farber Cancer Institute
Myeloid Malignancies, Acute Myeloid Leukemia
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
The goal of this clinical research study is to learn about the safety and effectiveness of giving KDS-1001 in combination with a standard stem cell transplant to patients with acute myeloid leukemia (AML), myelodysplastic…
- Conditions
- Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Trial name
- NCT05115630
- Testing
- Cyclophosphamide, Mesna, Filgrastim
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Diseases, Acute Myelogenous Leukemia
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
The goal of this clinical research study is to compare the effectiveness of receiving a combination of ondansetron and aprepitant to receiving ondansetron alone in helping to prevent nausea and/or vomiting in patients with Acute…
- Conditions
- Hematologic Diseases, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
- Trial name
- NCT00954941
- Testing
- Ondansetron, Aprepitant
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Thrombocytopaenia
A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)
Eltrombopag olamine (SB-497115-GR) is an orally bioavailable, small molecule thrombopoietin receptor agonist that may be beneficial in medical disorders associated with thrombocytopenia.
- Trial name
- NCT02158936
- Testing
- Eltrombopag, Azacitidine
- Where
- 155 sites in United States, Argentina and 28 more
- Volunteers
- 356 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndromes
Gemtuzumab in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Monoclonal antibodies such as gemtuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00022321
- Testing
- gemtuzumab ozogamicin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients
The study seeks to compare time from formal search to hematopoietic cell transplantation (HCT) for patients 18 years and older, randomized between haplo-cord search and matched unrelated donor (MUD) search for patients with acute…
- Trial name
- NCT02648932
- Testing
- Haplo-Cord Transplant, Matched Unrelated Donor Transplant
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Chicago
Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML
The addition of gemtuzumab ozogamicin (GO) in combination with Busulfan/Cyclophosphamide followed by AlloSCT in patients with high risk CD33+ AML/JMML/MDS will be safe and well tolerated.
- Conditions
- Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- High Risk (NCT00669890)
- Testing
- Gemtuzumab Ozogamicin, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New York Medical College
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
The Patient Cohort of the National Center for Precision Medicine in Leukemia
If for years the treatment strategy of leukemia and related disorders (LRDs, including acute leukemias and predisposition syndromes) has been based solely on whether the patient could receive or not intensive chemotherapy and…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome, Secondary Myelofibrosis in Myeloproliferative Disease
- Trial name
- eTHEMA (NCT05326919)
- Testing
- Biobanking
- Where
- 3 sites in France
- Volunteers
- 3,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris